Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bioxcel Therapeutics, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Bioxcel Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Bioxcel Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is BTAI. The reporting company's CIK number is 1720893.
The total value of stock buying since 2005 is $101,974.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2018-12-07||Mueller Peter (Director)||Buy||7,400||5.00||37,037|
|2018-12-06||Mueller Peter (Director)||Buy||1,395||5.00||6,981|
|2018-12-04||Mehta Vimal (CEO, President, Secretary)||Buy||1,000||5.12||5,120|
|2018-12-04||Yocca Frank (Chief Scientific Officer)||Buy||450||5.20||2,338|
|2018-12-04||Mueller Peter (Director)||Buy||4,007||5.12||20,515|
|2018-12-03||Mehta Vimal (CEO, President, Secretary)||Buy||1,000||5.15||5,150|
|2018-12-03||Yocca Frank (Chief Scientific Officer)||Buy||450||5.23||2,353|
|2018-12-03||Steinhart Richard I (Chief Financial Officer)||Buy||500||5.20||2,600|
|2018-11-30||Mehta Vimal (CEO, President, Secretary)||Buy||1,000||5.12||5,115|
|2018-11-30||Yocca Frank (Chief Scientific Officer)||Buy||450||5.20||2,339|
|2018-11-30||Steinhart Richard I (Chief Financial Officer)||Buy||500||5.00||2,500|
|2018-11-29||Nandabalan Krishnan (Director)||Buy||1,000||4.92||4,915|
|2018-11-29||Yocca Frank (Chief Scientific Officer)||Buy||500||5.02||2,511|
|2018-11-29||Steinhart Richard I (Chief Financial Officer)||Buy||500||5.00||2,500|
Insider trading activities including stock purchases, stock sales, and option exercises of BTAI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Bioxcel Therapeutics, Inc. (symbol BTAI, CIK number 1720893) see the Securities and Exchange Commission (SEC) website.